Press release
Boston, MA U.S.A. (January 20, 2023) — Allarity
Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage
pharmaceutical company developing novel oncology therapeutics
together with drug-specific DRP® companion diagnostics for
personalized cancer care today announced that the Company’s 2023
Annual Meeting of Stockholders (the “Meeting”), on January 19,
2023, at 1:00 p.m. (Eastern Time) was adjourned without any
business being conducted.
The Meeting was adjourned until Friday, February
3, 2023, to allow additional time for stockholders to vote on the
proposals set forth in the Company’s definitive proxy statement
filed with the U.S. Securities and Exchange Commission on December
6, 2022 (the “Proxy Statement”).
The adjourned Meeting will reconvene on February
3, 2023, at 1:00 p.m. (Eastern Time) virtually at
https://meetnow.global/MRJXJMN. The record date for the adjourned
Meeting remains the same, December 6, 2022. Stockholders of record
may attend the virtual webcast meeting by logging in through the
same method. During this adjournment, the Company will continue to
solicit votes from its stockholders regarding all proposals set
forth in the Proxy Statement. Stockholders who have already voted
their shares on the proposals contained in the Proxy Statement do
not need to vote again. Proxies previously submitted will be voted
at the adjourned Meeting, and stockholders who have previously
submitted a proxy or otherwise voted need not take any action.
Stockholders may use the Proxy Card that they
were originally provided with or vote in the manner as set forth in
the Proxy Statement. Stockholders who have questions or require any
assistance in voting their shares may contact the Company at
investorrelations@allarity.com.
Allarity encourages all stockholders, as of the
record date on December 6, 2022, who have not yet voted to do so
promptly.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR)
develops drugs for personalized treatment of cancer guided by its
proprietary and highly validated companion diagnostic technology,
the DRP® platform. The Company has a mature portfolio of three drug
candidates: stenoparib, a PARP inhibitor in Phase 2 development for
ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase
inhibitor; and the European rights to IXEMPRA® (Ixabepilone), a
microtubule inhibitor approved in the U.S. and marketed by R-PHARM
U.S. for the treatment of second-line metastatic breast cancer,
currently in Phase 2 development in Europe for the same indication.
Additionally, the Company has rights in two secondary assets:
2X-111, a liposomal formulation of doxorubicin for metastatic
breast cancer and/or glioblastoma multiforme (GBM), which is the
subject of discussions for a restructured out-license to Smerud
Medical Research International AS; and LiPlaCis®, a liposomal
formulation of cisplatin and its accompanying DRP®, being developed
via a partnership with Chosa Oncology AB for late-stage metastatic
breast cancer. The Company is headquartered in the United States
and maintains an R&D facility in Hoersholm, Denmark. For more
information, please visit the Company’s website at
www.Allarity.com.
About the Drug Response Predictor –
DRP® Companion
Diagnostic
Allarity uses its drug-specific DRP® to select
those patients who, by the genetic signature of their cancer, are
found to have a high likelihood of responding to the specific drug.
By screening patients before treatment, and only treating those
patients with a sufficiently high DRP® score, the therapeutic
response rate can be significantly increased. The DRP® method
builds on the comparison of sensitive vs. resistant human cancer
cell lines, including transcriptomic information from cell lines
combined with clinical tumor biology filters and prior clinical
trial outcomes. DRP® is based on messenger RNA from patient
biopsies. The DRP® platform has proven its ability to provide a
statistically significant prediction of the clinical outcome from
drug treatment in cancer patients in 37 out of 47 clinical studies
that were examined (both retrospective and prospective), including
ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The
DRP® platform, which can be used in all cancer types and is
patented for more than 70 anti-cancer drugs, has been extensively
published in peer reviewed literature.
Follow Allarity on Social
Media
Facebook:
https://www.facebook.com/AllarityTx/
LinkedIn:
https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements provide Allarity’s
current expectations or forecasts of future events. The words
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “would” and similar
expressions may identify forward-looking statements, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements related to clinical and commercial
potential due to the Company advancing dovitinib in combination
with another therapeutic candidate or other approved drug, any
statements related to ongoing clinical trials for stenoparib as a
monotherapy or in combination with another therapeutic candidate
for the treatment of advanced ovarian cancer, or ongoing clinical
trials (in Europe) for IXEMPRA® for the treatment of metastatic
breast cancer, and statements relating to the effectiveness of the
Company’s DRP® companion diagnostics platform in predicting whether
a particular patient is likely to respond to a specific drug. Any
forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that
results of a clinical study do not necessarily predict final
results and that one or more of the clinical outcomes may
materially change following more comprehensive reviews of the data,
and as more patient data become available, the risk that results of
a clinical study are subject to interpretation and additional
analyses may be needed and/or may contradict such results, the
receipt of regulatory approval for dovitinib or any of our other
therapeutic candidates or, if approved, the successful
commercialization of such products, the risk of cessation or delay
of any of the ongoing or planned clinical trials and/or our
development of our product candidates, the risk that the results of
previously conducted studies will not be repeated or observed in
ongoing or future studies involving our therapeutic candidates, and
the risk that the current COVID-19 pandemic will impact the
Company’s current and future clinical trials and the timing of the
Company’s preclinical studies and other operations. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our Form S-1 registration statement on
file with the Securities and Exchange Commission, available at the
Securities and Exchange Commission’s website at www.sec.gov, and as
well as discussions of potential risks, uncertainties and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
###
Company Contact:
Thomas
Jensen
Senior V.P. of
Investor Relations
investorrelations@allarity.com
U.S. Media Contact:
Mike Beyer
Sam Brown,
Inc.
+1 (312)
961-2502
mikebeyer@sambrown.com
EU Media Contact:
Thomas
Pedersen
Carrotize PR
& Communications
+45 6062
9390
tsp@carrotize.com
- Allarity Press Release - General Meeting Adjournment
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Feb 2023 to Mar 2023
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Mar 2022 to Mar 2023
